The BioProcess Insider editorial team sits down with Joshua Speidel, PhD, Partner, Latham Biopharm Group, Patrick Lucy, President and CEO, Lykan Biosciences, and Amélie Boulais, Head of Market Entry Strategy, Virus Based Therapeutics at Sartorius, to reflect on how the quarterly movements of the wider pharma industry are affecting the biomanufacturing space.

In this episode of the BioProcess Insider Expression Platform podcast, we explore the evolution of cell and gene therapy production with new COO of Lykan Bioscience, Patrick Lucy…

As a cell therapy candidate advances from discovery through clinical development, foundational decisions must be made by the product sponsor that will impact both scientific and commercial success. One of the biggest decisions is whether to build a manufacturing facility or outsource to a CDMO. In this e-book, we explore several key considerations that factor into making the best decision for your organization…

With decades of experience in biopharmaceutical production and, more specifically, in cell therapy manufacturing, the team at Lykan Bioscience has leveraged their expertise to…